WALTHAM, Mass., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that Company management will ring the Nasdaq Stock Market opening bell on Monday, February 9, 2015.
"Proteon has enjoyed much success over the last year including completing our initial public offering last October, initiating our first Phase 3 study last July, and privately raising $25 million from world-class investors last May," said Timothy Noyes, President and Chief Executive Officer of Proteon Therapeutics. "Ringing the opening bell at Nasdaq early in 2015 is a symbolic way for us to recognize what we accomplished in 2014 as we focus on the exciting work ahead for Proteon in 2015 and beyond."
Mr. Noyes and the Proteon management team will ring the opening bell on February 9, 2015 from 9:15 a.m. to 9:30 a.m. ET. A live webcast will be available at: https://new.livestream.com/Nasdaq/live.
About Proteon Therapeutics
Proteon Therapeutics Inc. is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass. For additional information, please visit www.proteontherapeutics.com.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.Nasdaq.com/ambition or www.Nasdaqomx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are, or may be deemed to be, "forward-looking statements." In some cases these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential," or, in each case, their negatives or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements are based upon the current beliefs and expectations of our management and are subject to significant risks and uncertainties, including those detailed in our filings with the Securities and Exchange Commission and those that relate to whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements for the period anticipated, whether data from early clinical trials will be indicative of the data that will be obtained from future clinical trials, whether PRT-201 will advance through the clinical trial process on the anticipated timeline and warrant submission for regulatory approval, whether such a submission would receive approval from the Food and Drug Administration (FDA) or equivalent foreign regulatory agencies on a timely basis or at all and whether we can successfully commercialize and market our PRT-201. In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Contact
George Eldridge, Senior Vice President and Chief Financial Officer
781-890-0102
geldridge@proteontherapeutics.com
Press Contact
Chris Erdman or Lynnea Olivarez, MacDougall Biomedical Communications
781-235-3060
proteon@macbiocom.com